May 8th 2024
The diagnostic aid platform, C.DIAG, utilizes artificial intelligence to assist with the diagnosis and treatment of dry eye disease.
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
1st Annual IKA Keratoconus Symposium: Front to Back and Everything In Between
View More
17th Annual Controversies in Modern Eye Care
View More
(COPE Credit) Community Practice Connection™: Pearls in Co-managing Glaucoma – Multidisciplinary Management in a Multitude of Treatment Options
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connection™: Pearls in Co-managing Glaucoma – Multidisciplinary Management in a Multitude of Treatment Options
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
Cases & Conversations™: Addressing Challenges In The Diagnosis And Management Of Neurotrophic Keratitis
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Vance Thompson Vision - Fargo
September 20, 2024
Register Now!
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Vance Thompson Vision - Montana
October 18, 2024
Register Now!
Vance Thompson Vision - Omaha
October 25, 2024
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
The pros and cons of the latest dry eye technology
October 7th 2015Over the last few years, there have been several advancements in ocular surface disease diagnostic and treatment technology. Not sure which ones are right for your practice? Milton Hom, OD, FAAO, and Ben Gaddie, OD, FAAO, share their advice.
The connection between dry eye and eyelashes
September 30th 2015While there are a myriad of associated concerns due to ocular surface inflammation, a few eyelash-related complications of note are trichiasis, acquired distachiasis, local madarosis, and poliosis. Each of these is in some way connected to dry eye.
A stepwise approach to diagnosing MGD
August 12th 2015Focusing on dry eye management is a great practice builder, but is not without challenges. These challenges lie in making the proper diagnosis, implementing new technology, properly training staff, developing an effective treatment plan and the time it takes to properly educate patients.
Using warm compresses to treat meibomian gland disease
Warm compresses (WCs) are commonly recommended as supplementary therapy for MGD as well as a number of other conditions of the eyelid. While the core therapy for MGD is to remove obstruction, which requires an in-office procedure, the therapeutic goal of adjunctive WC use is to heat the eyelids to help soften and partially melt any remaining material obstructing the glands.
5 things you don’t know about punctal plugs
August 12th 2015How often are you using punctal plugs in your practice? If your answer is similar to mine, it’s “not as often as I used to.” Classically, punctal plugs were a go-to treatment for dry eye patients. If artificial tears failed to yield relief, plugs were a logical next choice.
Fast forward 10 years: How will we treat myopia?
May 31st 2015Liverpool, UK-The British Contact Lens Association meeting features several panel discussion on a theme. Topics included a look into the future for managing myopia and contact lens discomfort. In addition, improve the success of your multifocal contact lens fits with expert suggestions.
Premium customer service takes your practice from good to great
April 23rd 2015What does it mean to have a premium practice? What does premium customer service deliver? These are common questions posed to medical practices and businesses as they seek out advice on how to thrive in today’s ever-competitive environment.
A new tool for managing ocular surface disease
March 13th 2015The mainstay of our therapy today consists of artificial tear preparations, surfactant lid cleansers, warm compresses for the eyelids, and the occasional antibiotic solution or ointment-this is the exact same therapy that was in vogue for treating OSD 25 years ago!
Diagnosing and treating lagophthalmos
March 10th 2015Since I read Dr. Robert Latkany’s study on nocturnal lagophthalmos in 2006,1 I am perpetually on the lookout for it, especially in the patients who present with dry eye symptoms. Sometimes it’s easy to spot lagophthalmos-sometimes, if you ask your patient about lid closure, they will report to you that they know about their incomplete lid closure, mostly when they sleep.
Identify Sjögren’s patients with Sjö test
February 12th 2015Are you providing the highest level of care for your dry eye patients? Testing with all the latest methods, osmolarity, MMP-9, TearScience’s LipiView, to name a few? Treating will a full armamentarium, specialized artificial tears, hot compresses, cyclosporine, steroids, punctual plugs, and more?
Screen younger patients for dry eye
January 16th 2015In my practice, we screen patients age 25 and over. This is a relatively arbitrary number, but I wanted to skew younger. We often think of dry eye disease as being an older person’s disease. There are a number of reasons why I decided to look at younger patients.
How hygiene products affect ocular surface and lids
December 17th 2014It’s sort of funny-one of my childhood recollections is a discussion with my mother (the PhD in organic chemistry) regarding the virtues of Phisohex (hexaclorrphene, Septisol), a facial cleaner. “Phisohex is pH balanced,” she said, “so it is better for your skin.” At the time, the pH comment wasn’t important to me. What was important was that my mother said I should use it, and therefore the characteristic 1970s green bottle of Phisohex was standard at each sink in our home.
Actavis, Allergan CEOs talk acquisition
November 25th 2014“The future is as bright as it’s ever been as a combined company-we’ll have an incredible amount of resources,” says Actavis CEO Brett Saunders. Saunders, Allergan CEO David Pyott, spoke exclusively with Optometry Times about the Allergan acquisition.